IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
At baseline patients received incobotulinumtoxinA (Xeomin) or placebo. Thereafter, all
patients who entered the extension period were treated with up to five injection sessions of
incobotulinumtoxinA (Xeomin) during the extension period.
Phase:
Phase 3
Details
Lead Sponsor:
Merz Pharmaceuticals GmbH
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA